NCT05330858

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Alumis Inc · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Conditions

• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	ESK-001	Oral tablet or liquid
DRUG	Rabeprazole	Oral Tablet

Timeline

• Start date: 2022-03-17
• Primary completion: 2022-06-30
• Completion: 2022-09-20
• First posted: 2022-04-15
• Last updated: 2023-05-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study